Molecular Imaging in Breast Cancer – Potential Future Aspects

Pinker, Katja; Bogner, Wolfgang; Gruber, Stephan; Brader, Peter; Trattnig, Siegfried; Karanikas, Georgios; Helbich, Thomas H.

doi:10.1159/000328275

Cited by 11 publications

(10 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally to increased spatial resolution, new and more specific markers for breast cancer are being developed to overcome 18 F-FDG PET/CT results, considering the poor 18 F-FDG specificity. Among these new markers one should highlight 18 F-16-alpha-17-beta-fluoroestradiol and 68 Ga-trastuzumab, which can non-invasively depict the tumor expression of estrogen and Her2 receptors, respectively, with potential to be useful in the assessment of therapeutic planning and response ( 28 ) .…”

Section: Discussionmentioning

confidence: 99%

Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo correlate the results of 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) performed with a specific protocol for assessment of breasts with histological/immunohistochemical findings in breast carcinoma patients.Materials and MethodsCross-sectional study with prospective data collection, where patients with biopsy-confirmed breast carcinomas were studied. The patients underwent PET/CT examination in prone position, with a specific protocol for assessment of breasts. PET/CT findings were compared with histological and immunohistochemical data.ResultsThe authors identified 59 malignant breast lesions in 50 patients. The maximum diameter of the lesions ranged from 6 to 80 mm (mean: 32.2 mm). Invasive ductal carcinoma was the most common histological type (n = 47; 79.7%). At PET/CT, 53 (89.8%) of the lesions demonstrated anomalous concentrations of 18F-FDG, with maximum SUV ranging from 0.8 to 23.1 (mean: 5.5). A statistically significant association was observed between higher values of maximum SUV and histological type, histological grade, molecular subtype, tumor diameter, mitotic index and Ki-67 expression.ConclusionPET/CT performed with specific protocol for assessment of breasts has demonstrated good sensitivity and was associated with relevant histological/immunohistochemical factors related to aggressiveness and prognosis of breast carcinomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In addition to increased spatial resolution, new and more specific markers for breast cancer are being developed in order to improve the value of FDG-PET/CT results. Among these new markers, attention should be drawn to 18 F-16-alpha-17-beta-fluoroestradiol and 68 Gatrastuzumab, which can non-invasively depict the tumor expression of estrogen and HER2 receptors, respectively, with potential usefulness for assessment of therapeutic planning and response [28].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of SUVmax of <sup>18</sup>F-FDG PET/CT in Early Stage Breast Cancer with No LN Metastasis

Murakami¹,

Fukushima²,

Tani³

et al. 2017

OJMI

View full text Add to dashboard Cite

Purpose: To investigate the correlation between SUVmax of FDG-PET/CT and pathological findings including prognostic factors in early-stage T1-T2 breast cancer patients with no LN metastasis. Materials and Methods: This retrospective study investigated 75 patients (mean age 58.9 years; age range 30 -82 years) with invasive breast cancer who underwent FDG-PET/CT for preoperative staging. All patients underwent subsequent surgery without prior neoadjuvant chemotherapy or endocrine therapy, and those who were confirmed to have T1-or T2-stage by histopathology with no LN metastasis were included. Two patients who had no perceptible FDG accumulation on PET/CT scans were excluded. The correlations between the SUVmax of the tumor and the pathological and immunohistochemical data were evaluated. Results: The mean SUVmax for the total 73 tumors was 5.46 ± 4.05. The mean SUVmax was 3.95 ± 3.28 for the T1 stage group (n = 36) and 7.23 ± 4.10 (p < 0.001) for the T2 stage group (n = 37). A high SUVmax was significantly associated with high nuclear grade (p < 0.001), negative hormone receptor status (p < 0.001), positive HER2 status (p = 0.008), and high Ki-67 status (p < 0.001), respectively. Conclusion: In T1-T2 breast cancer with no LN metastasis, the SUVmax of FDG-PET/CT had significant positive relationships with several prognostic parameters of pathological status. Even in early-stage breast cancer patients, pretreatment FDG-PET/CT is useful for predicting malignant behavior and prognosis).

show abstract

“…Recently, in an attempt to overcome these limitations, a PET imaging system exclusively for breast imaging has been developed. Positron emission mammography (PEM) is a new breast-dedicated device that promises to obtain a more accurate metabolic evaluation of breast lesions, thanks to a reduced distance between a patient's breast and the detection plates and therefore higher resolution than that of the wholebody technique (Pinker et al, 2011). PEM is equipped with two parallel photon detectors in a configuration similar to mammography compressors.…”

Section: Future Directionsmentioning

confidence: 99%

“…Nowadays, PEM and PET-MRI of the breast is mainly performed using 18 F-FDG. However, currently, specific radiotracers are being developed that will allow targeted molecular imaging of breast cancer (Pinker et al, 2011).…”

Section: Future Directionsmentioning

confidence: 99%

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

Iakovou

Giannoula

Gkantaifi

et al. 2018

European J Hybrid Imaging

View full text Add to dashboard Cite

Background: Breast cancer heterogeneity reflects the complex biology of this disease. Breast cancer subtypes, as identified either by immunohistochemistry (IHC) or by gene expression analysis, present different molecular characteristics and prognosis. In this context, molecular imaging techniques providing functional information, contribute in evaluating response to treatment and long-term prognosis among different subtypes. Nuclear imaging diagnosis modalities play an important role for conducting research on cancer biology and developing new treatment approaches. Positron Emission Tomography (PET) is a radionuclide based imaging method that has the potential to locate the tumor, define its staging, and monitor its response to treatment.Results: In the current study, we will review the utility of the most widely used molecular imaging technique, 18 F-fluorodeoxyglucose ( 18 F-FDG) PET, in order to determine the relationship between standardized uptake values (SUVs) and immunohistopathological factors, as well as to clarify whether PET is able to predict breast cancer phenotypes. Moreover, we will discuss the rising development of new radiopharmaceuticals in PET imaging, such as 18 F-fluoro-17-estradiol (FES), 18 F-fluoro-l-thymidine (FLT), 18 F-fluoromisonidazole (FISO), and 89 Zr-immuno-PET, which give more information about tumor characteristics. Conclusions: In order to improve clinical decision making, enabling hereafter more successful individualized therapies, it is imperative to combine PET radiopharmaceuticals and imaging techniques of critical biologic and pathologic phenomena, including ER, PR and HER2 expression, angiogenesis, hypoxia, apoptosis and metabolic changes in the microenviroment of breast tumors. BackgroundBreast cancer is the most frequently diagnosed noncutaneous malignancy in women worldwide, accounting for approximately 30% of all new cancer diagnoses and about 14% of all cancer deaths in women. About 63,410 new cases of female breast carcinoma in situ and 252,710 new cases of invasive breast cancer will be diagnosed in 2017 among United States (US) women. It is estimated that one in eight women will develop breast cancer during their life, while it is the second most common cause of cancer

show abstract

Molecular Imaging in Breast Cancer – Potential Future Aspects

Cited by 11 publications

References 125 publications

Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas

Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas

Prognostic Value of SUVmax of <sup>18</sup>F-FDG PET/CT in Early Stage Breast Cancer with No LN Metastasis

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

Contact Info

Product

Resources

About

Molecular Imaging in Breast Cancer – Potential Future Aspects

Cited by 11 publications

References 125 publications

Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas

Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas

Prognostic Value of SUVmax of &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT in Early Stage Breast Cancer with No LN Metastasis

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

Contact Info

Product

Resources

About

Prognostic Value of SUVmax of <sup>18</sup>F-FDG PET/CT in Early Stage Breast Cancer with No LN Metastasis